“FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junc

3/5/2019

We are pleased to inform you that a corporate press release, “FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma” has been issued  25 February 2019:

 

https://www.taihooncology.com/us/newsroom/press-releases/2019-02-25-LON-PM-US-1213-FDA-Approves-Gastric

 

Powered By GrowthZone